Document Type

Article

Publication Date

2022

Abstract

Aims: We sought to characterize the morbidity upon presentation of GTPS and compared it to patients with end-stage, hip osteoarthritis (OA) awaiting total hip arthroplasty (THA). We hypothesize that patients with GTPS will have similar or worse morbidity than hip OA patients.

Methods: This retrospective case-control study examined patient reported outcomes measures (PROMs) on activity limitations, quality of life, pain, and level of disability, in 156 GTPS patients (193 hips) and 300 pre-THA hip OA patients (326 hips). All patients presented at a single academic medical center. Patients with secondary hip conditions or previous hip surgeries were excluded from the study. PROMs were analyzed using an equivalence test and two-one-sided t-tests.

Results: Equivalence in mean UCLA Activity score between GTPS and OA groups were established with tolerance margin of ± 5. The difference in mean UCLA Activity score was 0.002 (95% CI -0.45 to 0.43, p < 0.01) between GTPS and OA patients. Equivalence in mean VAS score between GTPS and OA were established with tolerance margin of ± 10. The difference in mean VAS score was 0.35 (95% CI -0.86 to 0.16, p = 0.02). HOOSQol score was much worse in GTPS patients, placed well outside of the ± 10 tolerance margin and difference in means score was 1.72 (95% Cl -2.17 to -1.26, p = 0.99).

Conclusion: This cumulative evidence characterizes GTPS as painful and limiting in activities of daily living, as pre-THA hip OA, and with poorer quality of life scores than hip OA. Clinicians and researchers should consider GTPS as seriously as hip OA.

Academic Level

medical student

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.